-

06:54:46 AM

OCDX Stock News

OCDX - Ortho Clinical Diagnostics Holdings plc

05/16/22 4:45 PM

Nasdaq : OCDX

Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction

Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho

RHEA-AI

positive

05/04/22 4:05 PM

Nasdaq : OCDX

Ortho Clinical Diagnostics Reports First Quarter 2022 Results

Solid Revenue Performance Drives Financial Results Highlights • Core revenue declined (0.9%) to $495.0 million, and grew 0.6% in constant currency and 4.2% excluding CoV-2 assay sales, which was a 4% headwind • Growth, excluding CoV-2 assay sales, was driven by Americas, EMEA, and ASPAC regions

RHEA-AI

neutral

04/26/22 8:59 AM

Nasdaq : OCDX

covid-19

Ortho Clinical Diagnostics Recognized with Fifth Prestigious Edison Award for Highly Accurate COVID-19 Solution

Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious Gold 2022 Edison Award for its VITROS ®

RHEA-AI

very positive

04/20/22 4:14 PM

Nasdaq : OCDX

conferences

Ortho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on

RHEA-AI

neutral

03/09/22 8:55 AM

Nasdaq : OCDX

Ortho Clinical Diagnostics Wins Bronze Stevie® Award for Customer Service and Support

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro

RHEA-AI

positive

02/16/22 4:05 PM

Nasdaq : OCDX

earnings

Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2021 Results

Strong Revenue Growth Drives Financial Results Highlights • Fourth quarter Core revenue grew 3.5% to $518.9 million, or 4.3% in constant currency and 8.0% excluding CoV-2 assay sales • Fiscal year Core revenue grew 16.1% to $2.01 billion, or 14.6% in constant currency and 15.7% excluding CoV-2

RHEA-AI

very positive

01/24/22 8:00 AM

Nasdaq : OCDX

Ortho Clinical Diagnostics Holdings Plc (“Ortho”): Notice of UK Court Scheme Directions Hearing

Further to the joint announcement by Ortho and Quidel Corporation (“ Quidel ”) on December 23, 2021 of the signing of a definitive business combination agreement, Ortho announces that, as a preliminary procedural step in the process of implementing

RHEA-AI

positive

01/06/22 4:50 PM

Nasdaq : OCDX

earnings

Ortho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the

RHEA-AI

positive

01/03/22 8:00 AM

Nasdaq : OCDX

conferences

Ortho Clinical Diagnostics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40 th Annual J.P. Morgan

RHEA-AI

neutral

12/23/21 7:00 AM

Nasdaq : QDEL, OCDX

acquisition

Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics

Brings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Provides Quidel’ s expansive point-of-care diagnostics portfolio with access to Ortho’ s broad global reach across 130- plus countries, accelerating growth for Quidel’ s...

RHEA-AI

very positive

OCDX Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.orthoclinicaldiagnostics.com
Security nameOrtho Clinical Diagnostics Holdings plc
Issue typecs
SectorManufacturing
Sic code2835
Employees4500

About Ortho Clinical Diagnostics Holdings plc

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions. Because Every Test is a Life™, Ortho Clinical Diagnostics never stops innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate, reliable test results that support exceptional patient care. As a trusted partner of hospitals, hospital networks, blood banks, and labs around the world, Ortho Clinical Diagnostics serves the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs. Ortho Clinical Diagnostics is powered by Ortho Care™, its global, award-winning, holistic approach to service, which supports customers with best-in-class technical support, award-winning field support, and remote service and inventory support.